0.67
-2.86%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tiziana Life Sciences
Its shares trade under the ticker TLSA. It has been listed since 14 July 2008.
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. The firm develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Jul 2008
- Employees
- 10
- Website
- tizianalifesciences.com ↗
- Head office
- 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON, ENGLAND, X0, SW1Y 4LB
- Incorporated in
- D0
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Mr. Gabriele CerroneExecutive Chairman of the Board, since 2014$2.8m
- Mr. Ivor ElrifiChief Executive Officer, Executive Director, since 2024$4.7m
- Ms. Keeren ShahChief Financial Officer, Chief Operating Officer, since 2024
- Dr. William ClementiChief Development Officer
- Mr. John BrancaccioNon-Executive Independent Director$153,000
- Mr. Willy SimonNon-Executive Independent Director$153,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a clinical-stage biotechnology focus with a pipeline targeting neurodegenerative and lung diseases.
- Pipeline includes specific drug candidates like Foralumab, Anti IL-6R mAb, and Milciclib for various diseases.
- Company is based in London, UK, with a registered office in the United Kingdom.
Weaknesses
- Company has only 10 employees, indicating a small operational scale.
- IPO was in 2008, suggesting a long history but potentially limited recent capital raising.
- Company is clinical-stage, which implies high risk and dependency on successful clinical trials.
Opportunities
- Potential for drug candidates to address unmet medical needs in neurodegenerative and lung diseases.
- Growth in biotechnology sector could lead to increased investment and partnerships.
- Expansion of clinical pipeline may attract further funding and strategic collaborations.
Threats
- Clinical-stage companies face high failure rates in drug development and regulatory approval.
- Small employee count may limit research and development capacity and scalability.
- Competition in biotechnology sector is intense, with many companies targeting similar diseases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.